WALTHAM, Mass., Feb. 8 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today the amendment of its 1999 Supply Agreement with
GE Healthcare governing the manufacture of GE Healthcare's recombinant Protein
A. The amendment extends the term of the agreement through 2010, expands the
manufacturing to include an additional GE Healthcare protein and anticipates a
mechanism for the manufacturing of future proteins. The protein separations
business of GE Healthcare is a leader in the development, production and
marketing of protein separations products, which are used in the manufacture
of over 90 percent of all marketed biopharmaceutical drugs, including
monoclonal antibodies.
"We are pleased to expand our partnership with GE Healthcare, the market
leader in the production and marketing of process chromatography products,"
stated Walter C. Herlihy, President and Chief Executive Officer of Repligen.
"We anticipate continued robust growth in the monoclonal antibody market which
will drive increased demand for products based on Protein A."
"Repligen has demonstrated a solid performance as supplier over many years
and complements GE Healthcare with valuable expertise," stated Mats Grahn,
Vice President, Product Management for Protein Separations at GE Healthcare.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the
leader in the development of novel therapeutics for profound neuropsychiatric
disorders and autoimmune disease with particular emphasis on applications for
children. Repligen has a Specialty Pharmaceuticals business comprised of
rProtein A(TM) and SecreFlo(TM), the profits from which will be used to
partially support the development of our proprietary products. Repligen's
corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100,
Waltham, MA 02453. Additional information may be obtained from
http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements in this release do not constitute
guarantees of future performance. Investors are cautioned that statements in
this press release which are not strictly historical statements, including,
without limitation, statements regarding current or future financial
performance and position, management's strategy, plans and objectives for
future operations, plans and objectives for product development, plans and
objectives for present and future clinical trials and results of such trials,
plans and objectives for regulatory approval, litigation, intellectual
property, product development, manufacturing plans and performance such as the
anticipated growth in the monoclonal antibody market and our other target
markets and projected growth in product sales, constitute forward-looking
statements. Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ materially from
those anticipated, including, without limitation, risks associated with: the
success of current and future collaborative relationships, the market
acceptance of our products, our ability to compete with larger, better
financed pharmaceutical and biotechnology companies, new approaches to the
treatment of our targeted diseases, our expectation of incurring continued
losses, our uncertainty of product revenues and profits, our ability to
generate future revenues, our ability to raise additional capital to continue
our drug development programs, the success of our clinical trials, our ability
to develop and commercialize products, our ability to obtain required
regulatory approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual property
rights for our products, the risk of litigation regarding our intellectual
property rights, our limited sales and manufacturing capabilities, our
dependence on third-party manufacturers and value added resellers, our ability
to hire and retain skilled personnel, our volatile stock price, and other
risks detailed in Repligen's filings with the Securities and Exchange
Commission. Repligen assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
CONTACT:
Walter C. Herlihy, Ph.D.
President and Chief Executive Officer
(781) 250-0111, ext. 2000
Laura Whitehouse
Vice President, Market Development
(781) 250-0111, ext. 2306
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-250-0111, ext. 2000; or Laura
Whitehouse, Vice President, Market Development, +1-781-250-0111,
ext. 2306 both of Repligen Corporation
|
